In vitro cellular accumulation and cytotoxicity of liposomal and conventional formulations of daunorubicin and doxorubicin in resistant K562 cells

Anti-Cancer Drugs

Volumn 10, Issue 10, 1999, Pages 921-928

  Wang, Yuying ^a   Eksborg, Staffan ^b   Lewensohn, Rolf ^a   Lindberg, Annika ^b   Liliemark, Eva ^a  

^a Karolinska Krankenhaus   (Sweden)

^b KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Cellular drug accumulation; Cytotoxicity; Daunorubicin; Doxorubicin; Liposome; Multidrug resistance

Indexed keywords

ANTINEOPLASTIC AGENT; DAUNORUBICIN; DNA TOPOISOMERASE (ATP HYDROLYSING); DOXORUBICIN; GLYCOPROTEIN P; LIPOSOME;

ARTICLE; CANCER CELL CULTURE; CELL STRAIN K 562; CONTROLLED STUDY; CYTOTOXICITY; DRUG ACCUMULATION; ENZYME ACTIVITY; FLUOROMETRY; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN CELL; MULTIDRUG RESISTANCE; MYELOID LEUKEMIA; PRIORITY JOURNAL;

EID: 0033379879     PISSN: 09594973     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001813-199911000-00008     Document Type: Article

References (30)

1. Juliano RL, Ling V. A surface glycoprotein modulating drug permeability in Chinese hamster ovary cell mutants. Biochim Biophys Acta 1976; 455: 152-62.
2. Marie JP, Zittoun R, Sikic BI. Multidrug resistance (mdr1) gene expression in adult acute leukemias: correlations with treatment outcome and in vitro drug sensitivity. Blood 1991; 78: 586-92.
3. Gottesman MM, Pastan I. Biochemistry of multidrug resistance mediated by the multidrug transporter. Annu Rev Biochem 1993; 62: 385-427.
4. List AF, Kopecky KJ, Willman CL, et al. Benefit of cycloporine (CsA) modulation of anthracycline resistance in high-risk AML: a southwest oncology group (SWOG) study. Blood 1998; 92 (suppl 1): 312a.
5. Kim S. Liposomes as carriers of cancer chemotherapy. Current status and future prospects. Drugs 1993; 46: 618-38.
6. Gill PS, Espina BM, Muggia F, et al. Phase I/II clinical and pharmacokinetic evaluation of liposomal daunorubicin. J Clin Oncol 1995; 13: 996-1003.
7. Guaglianone P, Chan K, DelaFlor-Weiss E, et al. Phase I and pharmacologic study of liposomal daunorubicin (DaunoXome). Invest New Drugs 1994; 12: 103-10.
8. Money-Kyrle JF, Bates F, Ready J, et al. Liposomal daunorubicin in advanced Kaposi's sarcoma: a phase II study. Clin Oncol 1993; 5: 367-71.
9. Fossa SD, Aass N, Paro G. A phase II study of DaunoXome in advanced urothelial transitional cell carcinoma. Eur J Cancer 1998; 34: 1131-2.
10. Ford JM, Hait WN. Pharmacology of drugs that alter multidrug resistance in cancer. Pharmacol Rev 1990; 42: 155-99.
11. Thierry AR, Dritschilo A, Rahman A. Effect of liposomes on P-glycoprotein function in multidrug resistant cells. Biochem Biophys Res Commun 1992; 187: 1098-105.
12. Proffitt RT, Williams LE, Presant CA, et al. Liposomal blockade of the reticuloendothelial system: improved tumor imaging with small unilamellar vesicles. Science 1983; 220: 502-5.
13. Presant CA, Blayney D, Proffitt RT, et al. Preliminary report: imaging of Kaposi sarcoma and lymphoma in AIDS with indium-III-labelled liposomes [see comments]. Lancet 1990; 335: 1307-9.
14. Lasic DD. Doxorubicin in sterically stabilized liposomes. Nature 1996; 380: 561-2.
15. Pratt G, Wiles ME, Rawstron AC, et al. Liposomal daunorubicin: in vitro and in vivo efficacy in multiple myeloma. Hematol Oncol 1998; 16: 47-55.
16. Hu YP, Henry-Toulme N, Robert J. Failure of liposomal encapsulation of doxorubicin to circumvent multidrug resistance in an in vitro model of rat glioblastoma cells. Eur J Cancer 1995; 31A: 389-94.
17. Rahman A, Husain SR, Siddiqui J, et al. Liposome-mediated modulation of multidrug resistance in human HL-60 leukemia cells. J Nat Cancer Inst 1992; 84: 1909-15.
18. Larsson R, Kristensen J, Sandberg C, Nygren P. Laboratory determination of chemotherapeutic drug resistance in tumor cells from patients with leukemia, using a fluorometric microculture cytotoxicity assay (FMCA). Int J Cancer 1992; 50: 177-85.
19. Lowry OH, Rosebrough NJ, Far AL, Randall RJ. Protein measurement with the folin phenol reagent. J Biol Chem 1951; 193: 265-75.
20. Forssen EA, Coulter DM, Proffitt RT. Selective in vivo localization of daunorubicin small unilamellar vesicles in solid tumors. Cancer Res 1992; 52: 3255-61.
21. Forssen EA, Male-Brune R, Adler-Moore JP, et al. Fluorescence imaging studies for the disposition of daunorubicin liposomes (DaunoXome) within tumor tissue. Cancer Res 1996; 56: 2066-75.
22. Girard PM, Bouchaud O, Goetschel A, et al. Phase II study of liposomal encapsulated daunorubicin in the treatment of AIDS-associated mucocutaneous Kaposi's sarcoma. AIDS 1996; 10: 753-7.
23. Gill PS, Wernz J, Scadden DT, et al. Randomized phase III trial of liposomal daunorubicin versus doxorubicin, bleomycin, and vincristine in AIDS-related Kaposi's sarcoma. J Clin Oncol 1996; 14: 2353-64.
24. Ranson MR, Carmichael J, O'Byrne K, et al. Treatment of advanced breast cancer with sterically stabilized liposomal doxorubicin: results of a multicenter phase II trial [see comments]. J Clin Oncol 1997; 15: 3185-91.
25. Northfelt DW, Dezube BJ, Thommes JA, et al. Efficacy of pegylated-liposomal doxorubicin in the treatment of AIDS-related Kaposi's sarcoma after failure of standard chemotherapy. J Clin Oncol 1997; 15: 653-9.
26. Sadasivan R, Morgan R, Fabian C, Stephens R. Reversal of multidrug resistance in HL-60 cells by verapamil and liposome-encapsulated doxorubicin. Cancer Lett 1991; 57: 165-71.
27. Tritton TR. Cell surface actions of adriamycin. Pharmacol Ther 1991; 49: 293-309.
28. Allen TM, McAllister L, Mausolf S, Gyorffy E. Liposome-cell interactions. A study of the interactions of liposomes containing entrapped anti-cancer drugs with the EMT6, S49 and AEI (transport-deficient) cell lines. Biochim Biophys Acta 1981; 643: 346-62.
29. Horowitz AT, Barenholz Y, Gabizon AA. In vitro cytotoxicity of liposome-encapsulated doxorubicin: dependence on liposome composition and drug release. Biochim Biophys Acta 1992; 1109: 203-9.
30. Gabizon A, Chemla M, Tzemach D, et al. Liposome longevity and stability in circulation: effects on the in vivo delivery to tumors and therapeutic efficacy of encapsulated anthracyclines. J Drug Targeting 1996; 3: 391-8.